The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
D. A. Bota
No relevant relationships to disclose
Z. Eroglu
No relevant relationships to disclose
D. A. Reardon
No relevant relationships to disclose
B. D. Fu
No relevant relationships to disclose
J. Norfleet
No relevant relationships to disclose
A. Desjardins
No relevant relationships to disclose
M. E. Linskey
No relevant relationships to disclose
K. Peters
No relevant relationships to disclose
H. S. Friedman
No relevant relationships to disclose
J. J. Vredenburgh
No relevant relationships to disclose